Contineum Therapeutics, Inc. (CTNM)
| Market Cap | 387.16M +15.7% |
| Revenue (ttm) | n/a |
| Net Income | -63.46M |
| EPS | -1.76 |
| Shares Out | 39.27M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 265,893 |
| Open | 9.76 |
| Previous Close | 9.78 |
| Day's Range | 9.36 - 10.15 |
| 52-Week Range | 6.73 - 17.79 |
| Beta | 1.07 |
| Analysts | Buy |
| Price Target | 21.43 (+117.34%) |
| Earnings Date | Nov 3, 2026 |
About CTNM
Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing of small molecules different therapies for neuroscience, inflammation, and immunology indications in the United States. The company’s lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and chronic pain. It also develops PIPE-307, a novel, small-molecule inhibitor of the muscarinic type 1 receptor for depression and relapse-remitt... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 8 analysts, the average rating for CTNM stock is "Buy." The 12-month stock price target is $21.43, which is an increase of 117.34% from the latest price.
News
Contineum Therapeutics Transcript: Stifel 2026 Healthcare Conference 2026
PIPE-791 showed >90% LPA1 receptor occupancy across tested doses and is enrolling ~324 patients in a global, 26-week IPF study, with completion targeted for mid-2028. Cash of ~$245M was expected to fund operations through mid-2029.
Qureight's Fibrosis Imaging Biomarker Selected by Contineum Therapeutics as a Secondary Endpoint in Phase 2 PROPEL-IPF Clinical Trial
CAMBRIDGE, England & SAN DIEGO--(BUSINESS WIRE)--Qureight, an end-to-end imaging company providing enterprise-grade imaging and precision endpoints for clinical trials for lung and heart disease, and ...
Contineum reports Q3 EPS (49c), consensus (45c)
Cash, cash equivalents and marketable securities were $244.5 million as of September 30, 2026. Contineum (CTNM) believes its cash resources are sufficient to fund its planned operations through mid-20...
Contineum Therapeutics Reports Third-Quarter 2026 Financial Results
SAN DIEGO--(BUSINESS WIRE)--Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated small molecule therapies for in...
Contineum Therapeutics Earnings release: Q3 2026
Contineum Therapeutics released its Q3 2026 earnings on November 3, 2026, summarizing the period's financial results.
Contineum Therapeutics Quarterly report: Q3 2026
Contineum Therapeutics has published its Q3 2026 quarterly earnings report on November 3, 2026.
Contineum Therapeutics Slides: Corporate presentation
Contineum Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on November 3, 2026.
Contineum Therapeutics to Present at the Stifel 2026 Healthcare Conference
SAN DIEGO--(BUSINESS WIRE)--Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated small molecule therapies for in...
Contineum price target raised to $30 from $24 at Jones
Jones raised the firm’s price target on Contineum (CTNM) to $30 from $24 and keeps a Buy rating on the shares. The firm away from admilparant’s Phase 3 ALOFT-IPF trial…
Contineum downgraded to Neutral from Outperform at Baird
Baird analyst Charles Moore downgraded Contineum (CTNM) to Neutral from Outperform with a price target of $14, down from $19. The company’s hypothesis for greater LPA1R occupancy leading to greater…
Contineum downgraded to Neutral from Outperform at Baird
Baird downgraded Contineum (CTNM) to Neutral from Outperform with a price target of $14, down from $19. Contineum’s hypothesis for greater LPA1R occupancy leading to greater efficacy in idiopathic pul...
Jones sees greater room for Contineum’s PIPE-791 to differentiate
Jones reiterated a Buy rating and $24 price target on Contineum (CTNM) after a competitor report identified a Phase 3 long-term extension protocol amendment that newly classifies liver injury as…
Contineum Therapeutics Inc trading resumes
16:00 EDT Contineum (CTNM) Therapeutics Inc trading resumes
Contineum Therapeutics Inc trading halted, volatility trading pause
15:50 EDT Contineum (CTNM) Therapeutics Inc trading halted, volatility trading pause
Contineum price target lowered to $17 from $18 at Morgan Stanley
Morgan Stanley analyst Sean Laaman lowered the firm’s price target on Contineum (CTNM) to $17 from $18 and keeps an Equal Weight rating on the shares. Following the MOONLIGHT-1 study…
Contineum resumed at Early-Stage Biotech at Goldman Sachs
Goldman Sachs resumed coverage of Contineum (CTNM) with an Early-Stage Biotech rating. Goldman resumed coverage of the biotechnology sector, saying the group has continued to outperform despite a back...
Contineum Therapeutics Transcript: Morgan Stanley 24th Annual Global Healthcare Conference
China-origin innovation and AI are driving efficiency and new BD opportunities. PIPE-791, a once-daily LPA1R antagonist for IPF, is differentiated by its lack of dose titration and strong receptor occupancy. The company is funded through mid-2029, focusing on PROPEL-IPF while monitoring the evolving competitive landscape.
Contineum price target lowered to $24 from $26 at Jones
Jones lowered the firm’s price target on Contineum (CTNM) to $24 from $26 and keeps a Buy rating on the shares. PIPE-307 was well-tolerated but didn’t hit the primary endpoint…
Contineum price target lowered to $19 from $20 at Baird
Baird lowered the firm’s price target on Contineum (CTNM) to $19 from $20 and keeps an Outperform rating on the shares. The fim updated its model its announcement its PIPE-307…
Contineum, J&J's depression drug fails to meet mid-stage trial goal
Contineum Therapeutics said on Monday an experimental depression drug it developed with Johnson & Johnson failed to meet the main goal of a mid-stage study.
Contineum says MOONLIGHT-1 trial did not achieve its primary endpoint
The company states: “Contineum (CTNM) Therapeutics announced that the MOONLIGHT-1 trial did not achieve its primary efficacy endpoint. The trial evaluated improvement from baseline in the Montgomery-A...
Contineum down 11% atter MOONLIGHT-1 trial did not achieve endpoint
16:09 EDT Contineum (CTNM) down 11% atter MOONLIGHT-1 trial did not achieve endpoint
Contineum Therapeutics Reports Phase 2 Results for JNJ-5120/PIPE-307 for the Treatment of Major Depressive Disorder
SAN DIEGO--(BUSINESS WIRE)--Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated small molecule therapies for in...
Contineum Therapeutics to Present at the 2026 Morgan Stanley Global Healthcare Conference
SAN DIEGO--(BUSINESS WIRE)--Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated small molecule therapies for in...
Contineum initiated with an Outperform at LifeSci Capital
LifeSci Capital initiated coverage of Contineum (CTNM) with an Outperform rating and $24 price target